Fosfluridine tidoxil

    WARNING: This product is for research use only, not for human or veterinary use.

MedKoo CAT#: 530005

CAS#: 174638-15-4

Description: Fosfluridine tidoxil is a thymidylate synthase inhibitor potentially for the treatment of colorectal cancer, and breast cancer.

Chemical Structure

img
Fosfluridine tidoxil
CAS# 174638-15-4
Instruction

Theoretical Analysis

MedKoo Cat#: 530005
Name: Fosfluridine tidoxil
CAS#: 174638-15-4
Chemical Formula: C34H62FN2O10PS
Exact Mass: 740.38
Molecular Weight: 740.910
Elemental Analysis: C, 55.12; H, 8.44; F, 2.56; N, 3.78; O, 21.59; P, 4.18; S, 4.33

Price and Availability

This product is not in stock, which may be available by custom synthesis. For cost-effective reason, minimum order is 1g (price is usually high, lead time is 2~3 months, depending on the technical challenge). Quote less than 1g will not be provided. To request quote, please email to sales @medkoo.com or click below button.
Note: Price will be listed if it is available in the future.

Request quote for custom synthesis

Synonym: HDP-990006; HDP990006; HDP 990006

IUPAC/Chemical Name: 2-(decyloxy)-3-(dodecylthio)propyl (((2R,3S,4R,5R)-5-(5-fluoro-2,4-dioxo-3,4-dihydropyrimidin-1(2H)-yl)-3,4-dihydroxytetrahydrofuran-2-yl)methyl) hydrogen phosphate

InChi Key: LBBDGLOPGRGFDO-FKJRLRTPSA-N

InChi Code: InChI=1S/C34H62FN2O10PS/c1-3-5-7-9-11-13-14-16-18-20-22-49-26-27(44-21-19-17-15-12-10-8-6-4-2)24-45-48(42,43)46-25-29-30(38)31(39)33(47-29)37-23-28(35)32(40)36-34(37)41/h23,27,29-31,33,38-39H,3-22,24-26H2,1-2H3,(H,42,43)(H,36,40,41)/t27?,29-,30-,31-,33-/m1/s1

SMILES Code: O[C@@H]([C@H]([C@H](N1C(NC(C(F)=C1)=O)=O)O2)O)[C@H]2COP(O)(OCC(OCCCCCCCCCC)CSCCCCCCCCCCCC)=O

Appearance: Solid powder

Purity: >98% (or refer to the Certificate of Analysis)

Shipping Condition: Shipped under ambient temperature as non-hazardous chemical. This product is stable enough for a few weeks during ordinary shipping and time spent in Customs.

Storage Condition: Dry, dark and at 0 - 4 C for short term (days to weeks) or -20 C for long term (months to years).

Solubility: Soluble in DMSO

Shelf Life: >2 years if stored properly

Drug Formulation: This drug may be formulated in DMSO

Stock Solution Storage: 0 - 4 C for short term (days to weeks), or -20 C for long term (months).

HS Tariff Code: 2934.99.9001

More Info:

Biological target:
In vitro activity:
In vivo activity:

Preparing Stock Solutions

The following data is based on the product molecular weight 740.91 Batch specific molecular weights may vary from batch to batch due to the degree of hydration, which will affect the solvent volumes required to prepare stock solutions.

Recalculate based on batch purity %
Concentration / Solvent Volume / Mass 1 mg 5 mg 10 mg
1 mM 1.15 mL 5.76 mL 11.51 mL
5 mM 0.23 mL 1.15 mL 2.3 mL
10 mM 0.12 mL 0.58 mL 1.15 mL
50 mM 0.02 mL 0.12 mL 0.23 mL
Formulation protocol:
In vitro protocol:
In vivo protocol:

Molarity Calculator

Calculate the mass, volume, or concentration required for a solution.
=
x
x
g/mol

*When preparing stock solutions always use the batch-specific molecular weight of the product found on the vial label and SDS / CoA (available online).

Reconstitution Calculator

The reconstitution calculator allows you to quickly calculate the volume of a reagent to reconstitute your vial. Simply enter the mass of reagent and the target concentration and the calculator will determine the rest.

=
÷

Dilution Calculator

Calculate the dilution required to prepare a stock solution.
x
=
x

1: Venhoff AC, Lebrecht D, Reuss FU, Heckl-Ostreicher B, Wehr R, Walker UA, Venhoff N. Mitochondrial DNA depletion in rat liver induced by fosalvudine tidoxil, a novel nucleoside reverse transcriptase inhibitor prodrug. Antimicrob Agents Chemother. 2009 Jul;53(7):2748-51. doi: 10.1128/AAC.00364-09. PubMed PMID: 19433557; PubMed Central PMCID: PMC2704664.

2: Miller MM, Fogle JE. Administration of Fozivudine tidoxil as a single-agent therapeutic during acute feline immunodeficiency virus infection does not alter chronic infection. Viruses. 2012 Jun;4(6):954-62. doi: 10.3390/v4060954. PubMed PMID: 22816034; PubMed Central PMCID: PMC3397356.

3: Fogle JE, Tompkins WA, Campbell B, Sumner D, Tompkins MB. Fozivudine tidoxil as single-agent therapy decreases plasma and cell-associated viremia during acute feline immunodeficiency virus infection. J Vet Intern Med. 2011 May-Jun;25(3):413-8. doi: 10.1111/j.1939-1676.2011.0699.x. PubMed PMID: 21457319; PubMed Central PMCID: PMC3785110.

4: Fozivudine: BM 211290, fozivudine tidoxil, FZT, HDP 990002, W 09726867. Drugs R D. 2004;5(1):41-3. Review. PubMed PMID: 14725491.

5: Bogner JR, Roecken M, Herrmann DB, Boerner D, Kaufmann B, Gürtler L, Plewig G, Goebel FD. Phase I/II trial with fozivudine tidoxil (BM 21.1290): a 7 day randomized, placebo-controlled dose-escalating trial. Antivir Ther. 1997 Dec;2(4):257-64. PubMed PMID: 11327445.

6: Girard PM, Pegram PS, Diquet B, Anderson R, Raffi F, Tubiana R, Sereni D, Boerner D. Phase II placebo-controlled trial of fozivudine tidoxil for HIV infection: pharmacokinetics, tolerability, and efficacy. J Acquir Immune Defic Syndr. 2000 Mar 1;23(3):227-35. PubMed PMID: 10839658.

7: Bogner JR, Boerner D, Mühlhöfer A, Thoma-Greber E, Herrmann DB, Hoegl L, Roecken M, Jost V, Goebel FD. Single dose, dose-escalating trial with fozivudine tidoxil (BM 21.1290). Antivir Ther. 1997 Dec;2(4):249-56. PubMed PMID: 11327444.